New triple inhaler shows promise for COPD patients

NCT ID NCT04876677

Completed Disease control Sponsor: Chiesi Farmaceutici S.p.A. Source: ClinicalTrials.gov ↗

First seen Apr 15, 2026 · Last updated May 12, 2026 · Updated 2 times

Summary

This study tested whether switching from a standard two-drug inhaler to a newer three-drug extrafine inhaler could improve lung function in people with advanced COPD. Twenty-five participants were followed for several weeks, and their airways were measured using special 3D imaging. The goal was to see if the new inhaler could open airways and improve breathing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

AZ Delta

Roeselare, Belgium
AZ Zeno Knokke-Heist

Knokke, Belgium
CRU Hungary Ltd

Miskolc, Hungary
Dr. Kenessey Albert Hospital

Balassagyarmat, Hungary
Medlmprove BV

Kontich, 2550, Belgium
National Koranyi Institute for TB and Pulmonology

Budapest, Hungary
OLV Hospital Aalst

Aalst, Belgium
Pneumocare Scrl

Erpent, Belgium

Conditions

Explore the condition pages connected to this study.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE